T
TubeFolio
Back to Dashboard

NVIDIA GTC 2026 Interviews: AI Is Only Becoming More Important

Amit KukrejaAug 9, 2026

Summary

Amit explores the transition from reasoning-based AI models to autonomous agents through interviews with NVIDIA leadership at the GTC event. Amit argues that we are entering the 'moment of agents,' where software like OpenClaw and NVIDIA's NemoClaw provides unbounded autonomy to perform tasks ranging from coding to managing household systems. Amit emphasizes that the future of the software industry will shift from selling individual seats to offering 'agents-as-a-service,' where AI agents act as super-engineers and knowledge workers rather than simple replacements for human labor.

In the realm of healthcare, Amit highlights NVIDIA's role as an accelerated computing platform rather than just a chip manufacturer. Amit states that AI is being used to revolutionize three key areas: digital devices (like surgical robotics), digital biology (drug discovery), and digital health (physician empowerment). Amit points out that the traditional 10-year, $2 billion drug discovery process is being disrupted by 'in-silico' exchange loops that allow for low-latency scientific discovery. Amit also notes a trend toward 'democratized healthcare,' where consumers use AI models to interpret genomic and blood data to take proactive control of their health.

NVIDIA (NVDA): Amit showcases NVIDIA as the essential substrate for the agentic AI wave, focusing on the release of NemoClaw and the OpenShell sandbox for enterprise security. Amit highlights NVIDIA's massive $1 billion co-innovation lab commitment with Eli Lilly as a testament to their dominance in the future of digital biology. Amit views the company's strategy of being 'the most open' AI company—releasing checkpoints, pre-training data, and papers—as a critical competitive advantage.
ServiceNow (NOW): Amit references ServiceNow as a primary success story where 90% of L1 service tickets are now handled by autonomous agents. Amit argues that this does not replace engineers but allows them to focus on complex L2 issues with better context provided by the AI. Amit emphasizes that this efficiency gain is a blueprint for how all legacy software companies must evolve to remain valuable.
Eli Lilly (LLY): Amit details a significant partnership where Eli Lilly and NVIDIA are investing $1 billion over five years to build a co-innovation lab. Amit states that this lab will collocate AI scientists with drug hunters to generate massive datasets and train models that understand the language of chemistry. Amit explains that this collaboration aims to create a low-latency discovery loop to find cures more effectively than traditional methods.

Mentioned Stocks

NVDA
Sentiment: BUYAction: RECOMMENDED

Reasoning: Amit views NVIDIA as the foundational platform for both the next generation of autonomous software agents and the digital transformation of healthcare. Amit highlights their open-source approach to models and data, alongside high-profile partnerships like the $1 billion lab with Eli Lilly, as reasons for their continued market dominance.

Loading chart...
NOW
Sentiment: BUYAction: RECOMMENDED

Reasoning: Amit identifies ServiceNow as a leader in applying agentic AI to real-world business problems, specifically noting that 90% of their L1 support tickets are now automated. Amit argues this proves the productivity thesis of AI in the enterprise sector.

Loading chart...
LLY
Sentiment: BUYAction: RECOMMENDED

Reasoning: Amit highlights the $1 billion long-term partnership between Eli Lilly and NVIDIA as a major catalyst for the stock. Amit notes that their commitment to building 'in-silico' discovery loops will drastically reduce the time and cost associated with drug development.

Loading chart...